Gossamer Bio Inc GOSS.OQ GOSS.O is expected to show a rise in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024
The San Diego California-based company is expected to report revenue of $6.834 million, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Gossamer Bio Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Gossamer Bio Inc is $8.00, above its last closing price of $1.19.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.12 | -0.15 | -0.14 | Beat | 5.3 |
Jun. 30 2024 | 0.31 | 0.23 | 0.22 | Missed | -3.9 |
Mar. 31 2024 | -0.19 | -0.19 | -0.19 | Met | -0.5 |
Dec. 31 2023 | -0.19 | -0.21 | -0.21 | Met | -1 |
Sep. 30 2023 | -0.24 | -0.26 | -0.21 | Beat | 17.8 |
Jun. 30 2023 | -0.48 | -0.49 | -0.45 | Beat | 8 |
Mar. 31 2023 | -0.52 | -0.53 | -0.52 | Beat | 1.8 |
Dec. 31 2022 | -0.62 | -0.62 | -0.59 | Beat | 5.3 |
This summary was machine generated February 28 at 13:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。